Cole Pinnow - 14 Jan 2025 Form 4 Insider Report for Cogent Biosciences, Inc. (COGT)

Role: Chief Commercial Officer
Signature: /s/ Evan D. Kearns, Attorney-in-Fact
Issuer symbol: COGT
Transactions as of: 14 Jan 2025
Net transactions value: +$332,412
Form type: 4
Filing time: 15 Jan 2025, 07:00:04 UTC
Previous filing: 29 May 2024
Next filing: 27 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	COGT	Common Stock	Purchase	$332,412	+43,750	+2085%	$7.60	45,848	14 Jan 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported represents the weighted average purchase price per share. The shares were purchased in multiple transactions at prices ranging from $7.53 to $7.60. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price.
F2	Includes an aggregate of 1,398 shares acquired by the Reporting Person under the Issuer's 2018 Employee Stock Purchase Plan on December 31, 2024.

Content

The price reported represents the weighted average purchase price per share. The shares were purchased in multiple transactions at prices ranging from $7.53 to $7.60. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price.

Includes an aggregate of 1,398 shares acquired by the Reporting Person under the Issuer's 2018 Employee Stock Purchase Plan on December 31, 2024.